TY - JOUR ID - 70390 TI - Concurrent Chemo- Radiobrachytherapy with Cisplatin and Medium Dose Rate Intra- Cavitary Brachytherapy for Locally Advanced Uterine Cervical Cancer JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Aghili, Mahdi AU - Andalib, Bahram AU - Karimi Moghaddam, Zhaleh AU - Maddah Safaei, Afsaneh AU - Amoozgar Hashemi, Farnaz AU - Mousavi Darzikolaei, Nima AD - Radiation Oncology Research Center, Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Department of Radiation Oncology, Zanjan University of Medical Sciences, Zanjan, Iran. Y1 - 2018 PY - 2018 VL - 19 IS - 10 SP - 2745 EP - 2750 KW - Uterin Cervical Cancer KW - MDR KW - Brachytherapy DO - 10.22034/APJCP.2018.19.10.2745 N2 - Objective: Cervical carcinoma is the third most common gynecologic cancer, after ovarian and uterine cancersin Iran. The aim of this study was to evaluate the efficacy (response rate) and toxicity of adding Medium Dose Rate(MDR) brachytherapy with concurrent chemotherapy to External Beam Radiotherapy (EBRT) for the treatment oflocally advanced uterine cervical carcinoma. Methods: This phase I-II study was conducted in 2007-2008 at the cancerinstitute, Tehran University of Medical Sciences. Patients were treated with pelvic EBRT (50 Gy in 25 Fraction) withconcomitant chemotherapy to obtain tumor shrinkage and permit optimal intra-cavitary placement. One week after thecompletion of EBRT, patients were treated by 12 Gy MDR Intra-cavitary brachytherapy for two periods of one daywith a one week interval and concomitant platinum based chemotherapy. Response rate was evaluated by gynecologicphysical examination and pelvic MRI +- GD within three months of treatment. Acute and late toxicity were assessedusing Radiation Therapy Oncology Group criteria. Results: A total of 33 patients with locally advanced cervical cancerwere treated according to the above described treatment protocol. The patients mean age was 53.2 (range 31–78) years.Three months after the completion of treatment, the complete clinical, pathologic and radiologic response rate accordingto WHO-criteria was 81.8% (27 patients). Six cases had a partial response or stable disease. After 48 months, averagedisease free survival periods were 45.1, 23.0, 33.4 and 8 months for stage IIB, IIIA, IIIB and: IVA lesions (according toThe International Federation of Gynecology and Obstetrics staging system). The most frequently observed side effectswere leukopenia, anemia, proctitis, cystitis, nausea and vomiting (mostly grade 1 and 2). Conclusion: Concomitantbrachytherapy and chemotherapy with platinum compounds can be well tolerated and is effective in the treatment oflocally advanced cervical cancer. UR - https://journal.waocp.org/article_70390.html L1 - https://journal.waocp.org/article_70390_4346eadb688062bee03912c3ec969c82.pdf ER -